SI-BONE Earnings Reports

SI-BONE delivered strong revenue growth and positive adjusted EBITDA in Q3 2025, along with a reduced net loss, improved gross margin, and growth across both U.S. and international markets.

SI-BONE delivered a robust second quarter in 2025, with worldwide revenue increasing by 21.7% to $48.6 million. The company achieved positive Adjusted EBITDA of $1.0 million and generated $1.1 million in net cash, demonstrating strong operational performance and disciplined execution. Net loss improved by 31.2% to $6.2 million.

SI-BONE, Inc. announced a strong start to 2025, with worldwide revenue increasing by 24.9% to $47.3 million and U.S. revenue growing by 26.6% to $44.8 million. The company achieved positive adjusted EBITDA of $0.5 million, a significant improvement from a loss in the prior year, and reduced net cash usage by 31.7%.

SI-BONE, Inc. delivered a strong performance in Q4 2024, with worldwide revenue reaching $49.0 million, a 26% increase year-over-year, and achieving positive adjusted EBITDA of $1.9 million, marking a significant improvement from the previous year.

SI-BONE reported a strong Q3 2024 with worldwide revenue of $40.3 million, representing a growth of approximately 19%. The company significantly improved its financial performance, reducing its net loss by approximately 34% and its Adjusted EBITDA loss by approximately 94%. They expect to achieve positive Adjusted EBITDA in the fourth quarter of 2024.

SI-BONE, Inc. reported strong Q2 2024 financial results, with worldwide revenue of $40.0 million, representing a growth of approximately 20%. The company's net loss improved by approximately 20%, and they ended the quarter with $151.5 million in cash and equivalents. They increased 2024 revenue guidance to $165 million - $167 million and expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024.

SI-BONE, Inc. reported a worldwide revenue of $37.9 million, a 16% increase compared to the prior year period. The company updated its 2024 worldwide revenue guidance to be in the range of $164 million to $166 million.

SI-BONE reported a 22% increase in worldwide revenue for Q4 2023, driven by a 22% increase in U.S. revenue. The company's gross margin was 74%, impacted by procedure and product mix and an excess inventory reserve. Net loss improved slightly to $11.0 million, and adjusted EBITDA loss decreased to $4.8 million.

SI-BONE, Inc. reported record worldwide revenue of $34.0 million for Q3 2023, representing approximately 29% growth over the corresponding period in 2022. The company's annual guidance was increased to $136 million - $137 million, implying annual growth of 28%-29%.

SI-BONE, Inc. reported a strong second quarter with record worldwide revenue of $33.3 million, representing a 30% increase year-over-year. U.S. revenue also reached a record $31.2 million, a 31% increase year-over-year. The company's operating loss improved by 33% and net loss improved by 39%.

SI-BONE, Inc. reported record worldwide revenue of $32.7 million for Q1 2023, a 46% increase year-over-year. U.S. revenue also hit a record at $30.5 million, a 50% increase. The company's annual revenue guidance was increased to $128 million - $131 million, reflecting anticipated growth of 20%-23%.

SI-BONE, Inc. reported a 27% increase in worldwide revenue for Q4 2022, reaching $32.0 million. U.S. revenue increased by 28% to $30.0 million. The company's net loss was $11.2 million, or $0.32 per diluted share, and the adjusted EBITDA loss improved by 54% to $4.2 million.

SI-BONE reported a record worldwide revenue of $26.4 million for Q3 2022, representing a 19% increase over the corresponding period in 2021. The company's U.S. revenue also hit a record of $24.6 million, a 21% increase year-over-year. The gross margin was 84% for the third quarter 2022.

SI-BONE, Inc. reported record worldwide revenue of $25.6 million for the second quarter 2022, representing approximately 15% increase over the corresponding period in 2021. The company's gross margin was 86% for the second quarter 2022.

SI-BONE, Inc. reported a 10% increase in worldwide revenue, reaching $22.4 million for the first quarter of 2022. U.S. revenue increased by 9% to $20.4 million, and the gross margin was 87%. The company's operating loss was $16.9 million, and the net loss was $17.4 million, or $0.52 per diluted share.

SI-BONE, Inc. reported a 14% increase in worldwide revenue for Q4 2021, reaching $25.2 million, and a gross margin of 87%. The company's operating loss was $13.9 million, and net loss was $14.5 million, or $0.43 per diluted share.

SI-BONE reported a record worldwide revenue of $22.3 million for Q3 2021, representing a 9% increase over the corresponding period in 2020. The company's gross margin was 89% for the third quarter 2021. They are updating the full year 2021 total revenue guidance to be approximately $89 million to $90 million, representing growth of 21% to 23% compared to full year 2020.

SI-BONE, Inc. reported a record worldwide revenue of $22.2 million for Q2 2021, a 58% increase compared to Q2 2020. The company's U.S. revenue increased by 53% to $20.2 million. The company is maintaining its full year 2021 total revenue guidance to be approximately $92 million to $94 million.

SI-BONE, Inc. reported a 22% increase in worldwide revenue, reaching $20.4 million for the first quarter of 2021, compared to $16.8 million in the corresponding period in 2020. U.S. revenue increased by 23% to $18.8 million. The company's net loss was $12.2 million, or $0.37 per diluted share.

SI-BONE, Inc. reported a 12% increase in worldwide revenue for the fourth quarter of 2020, reaching $22.1 million. The company's U.S. revenue also increased by 12% to $20.7 million. Despite the lingering effects of the COVID-19 pandemic, SI-BONE sees strong underlying momentum in its business and provides full year 2021 revenue guidance of $92 million to $94 million, or 25% to 28% growth.

SI-BONE reported a 26% increase in worldwide revenue, reaching $20.4 million for Q3 2020, with U.S. revenue up by 27% to $18.9 million. The company's operating loss decreased to $8.7 million, and net loss improved to $9.5 million, or $0.33 per diluted share.

SI-BONE, Inc. reported a decrease in revenue for the second quarter of 2020, primarily due to the impact of the COVID-19 pandemic on case volumes. Revenue was $14.0 million, a 14% decrease compared to the previous year. The company completed debt refinancing and obtained positive coverage by Aetna.

SI-BONE, Inc. reported a 12% increase in revenue to $16.8 million for Q1 2020, with U.S. revenue up 14% to $15.3 million. The company's operating loss was $11.9 million, and net loss was $12.8 million, or $0.47 per diluted share.

SI-BONE reported a 27% increase in worldwide revenue, reaching $19.8 million for Q4 2019. U.S. revenue grew by 28% to $18.5 million. However, the company's operating loss widened to $8.5 million due to increased operating expenses.